| abstract |
Specific binding agents are disclosed, such as fully human antibodies that bind angiopoietin-2. In addition, fragments of heavy chains, fragments of light chains and regions that define complementarity in the composition of antibodies, as well as methods for producing and using these antibodies are disclosed. |